|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| C07K 16/30 | (2006.01) |
| (11) | Number of the document | 3341015 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16840215.4 |
| Date of filing the European patent application | 2016-08-26 | |
| (97) | Date of publication of the European application | 2018-07-04 |
| (45) | Date of publication and mention of the grant of the patent | 2021-07-28 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/049016 |
| Date | 2016-08-26 |
| (87) | Number | WO 2017/035480 |
| Date | 2017-03-02 |
| (30) | Number | Date | Country code |
| 201562210279 P | 2015-08-26 | US |
| (72) |
SCHNORR, Peter , US
CHHABRA, Akanksha , US
SHIZURU, Judith A. , US
WEISSMAN, Irving L. , US
WEISKOPF, Kipp Andrew , US
|
| (73) |
The Board of Trustees of the Leland Stanford
Junior University ,
Office of the General Counsel
Building 170, Third Floor, Main Quad
P.O. Box 20386, Stanford, CA 94305-2038,
US
|
| (54) | ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST |
| ENHANCED DEPLETION OF TARGETED CELLS WITH CD47 BLOCKADE AND AN IMMUNE COSTIMULATORY AGONIST |